¹Bone Marrow Transplant Unit, Hospital Saint-Louis, Paris, France

Correspondence: Dr E Gluckman, Service d'Hématologie-Greffe de Moelle, Hôpital Saint-Louis 1, avenue Claude Vellefaux, 75475 Paris Cedex 10, France; E-mail: eliane.gluckman@sls.ap-hop-paris.fr

Received 30 November 2004; Accepted 17 May 2005; Published online 27 June 2005.

Abstract

Poor graft function (PGF) is a frequent cause of morbidity after allogeneic hematopoietic stem cell transplantation (allo-HSCT). To study the value of granulocyte colony-stimulating factor (G-CSF) in PGF, we retrospectively analyzed 81 episodes of PGF in 66 patients transplanted from 01/94 to 01/99 from an HLA-identical sibling (n=45) or an unrelated (n=21) donor. Median age was 29 years, 55 patients had malignancies. A total of 11 patients received a CD34+ selected graft. Viral infections (25%), myelotoxic drug (33%), fungal/bacterial infections (14%), and GVHD (31%) were present before PGF diagnosis. Median time from allo-HSCT to PGF was 75 (25–474) days. All patients were treated with G-CSF. In 77/81 episodes, there was a response that was sustained in 57. A total of 27 patients presented an increase of white cell count (WBC) >0.1 10⁹/l after 3 days of G-CSF. The 5-year survival was 37% and was significantly better in patients with increased WBC >0.1 10⁹/l after 3 days of G-CSF (65 vs 18%, P<0.0001). In multivariate analysis, increased WBC >0.1 10⁹/l after 3 days of G-CSF (P=0.002) was associated with better survival, while BuCy-based conditioning (P=0.02) and GVHD (P=0.005) were associated with higher risk of death. In conclusion, hematological response after 3 days with G-CSF predicted a better survival for patients with PGF after allo-SCT.